NCT03921073终止2 期
A Phase II Study of Talimogene Laherparepvec (T-VEC) in the Treatment of Locally Advanced Cutaneous Angiosarcoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Overall Response Rate
研究概览
简要总结
This is a single-arm study evaluating the efficacy of injecting Talimogene Laherparepvec T-VEC into Cutaneous Angiosarcoma tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have histologically confirmed CA without visceral or CNS metastases, with resection deemed of no benefit by technical or oncologic principles, and have progressed on at least one line of systemic therapy
- •Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded by digital photography) as >6 mm with calipers or a ruler.
- •Eastern Cooperative Oncology Group performance status 0-1 (Karnofsky >70%).
- •Participants must have normal organ and marrow function as defined below:
- •Hematological
- •Absolute neutrophil count > 1500/mm3 (1.5x109/L)
- •Platelet count >75,000/mm3 (7.5x109/L)
- •Hemoglobin >8 g/dL (without need for hematopoietic growth factor or transfusion support)
- •Serum creatinine ≤1.5 x upper limit of normal (ULN), OR 24-hour creatinine clearance >60 mL/min for subject with creatinine levels > 1.5 x ULN. (Note: Creatinine clearance need not be determined if the baseline serum creatinine is ≤1.5 x ULN. . Creatinine clearance should be determined per institutional standard).
- •Serum bilirubin ≤1.5 x ULN OR direct bilirubin ≤ ULN for a subject with total bilirubin level > 1.5 x ULN
- •Aspartate aminotransferase (AST) ≤2.5 x ULN OR <5 x ULN, if liver metastases present and injection does not involve a visceral lesion
- •Alanine aminotransferase (ALT) ≤2.5 x ULN OR <5 x ULN, if liver metastases present and injection does not involve a visceral lesion
- •Coagulation
- •International normalization ratio (INR) or prothrombin time (PT) ≤1.5 x ULN, unless the subject is receiving anticoagulant therapy, in which case PT and partial thromboplastin time (PTT)/ activated PTT (aPTT) must be within therapeutic range of intended use of anticoagulants.
- •PTT or aPTT ≤1.5 x ULN, unless the subject is receiving anticoagulant therapy as long as PT and PTT/aPTT is within therapeutic range of intended use of anticoagulants.- Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to enrollment. If urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
排除标准
- •Participants with a second active malignancy, exceptions are localized non-melanoma skin cancers or in situ carcinoma
- •Participants receiving any other investigational agents
- •Participants with tumor(s) in direct contact or encasing a major blood vessel, those with ulceration and/or fungation onto the skin surface, and those with history of re-irradiation or prior lymph node neck dissection to a field involving the carotid arteries
- •History or evidence of active autoimmune disease that requires systemic treatment (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Evidence of clinically significant immunosuppression such as the following:
- •Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease.
- •concurrent opportunistic infection.
- •receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment.
- •Active herpetic skin lesions or prior complications of HSV-1 infection (e.g., herpetic keratitis or encephalitis).
- •Requires intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use.
- •Previous treatment with talimogene laherparepvec or any other oncolytic virus.
- •Prior therapy with tumor vaccine.
- •Received live vaccine within 28 days prior to enrollment.
- •Prior immunosuppressive, chemotherapy, radiotherapy (in which the field encompassed a planned injection site), biological cancer therapy, or major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment.
- •Prior radiotherapy in which the field does not overlap the injection sites or non-immunosuppressive targeted therapy within 14 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 14 days prior to enrollment
- •Currently receiving treatment with another investigational device or drug study, or < 28 days since ending treatment with another investigational device or drug study(s).
- •Other investigational procedures while participating in this study are excluded.
- •Known to have acute or chronic active hepatitis B infection, hepatitis C infection, or human immunodeficiency virus (HIV) infection.
- •History of other malignancy within the past 5 years with the following exceptions: adequately treated non melanoma skin cancer, cervical carcinoma in situ, breast ductal carcinoma in situ, or prostatic intraepithelial neoplasia without evidence of disease at the time of enrollment
- •Participant has known sensitivity to talimogene laherparepvec or any of its components to be administered during dosing.
- •Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec.
- •Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of talimogene laherparepvec.
- •Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec.
- •Participants who are unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for HSV-1 induced complications such as immunosuppressed individuals, individuals known to have HIV infection, pregnant women, or infants under the age of 3 months, during talimogene laherparepvec treatment and through 30 days after the last dose of talimogene laherparepvec.
研究组 & 干预措施
Intralesional injection of T-VEC
Experimental
Participants will undergo intralesional injections of up to 4 cc of 10^6 plaque-forming units (PFU)/mL of T-VEC. Dose is dependent on the diameter of the lesions to be injected (volume injected is related to diameter of lesion(s) at time point 0). Three weeks later and every other week thereafter, the participants will be injected with up to 4 cc of 10^8 PFU/mL, with dose dependent on the diameter of the lesion(s) to be injected. Participants may be treated for up to 12 months.
干预措施: T-VEC (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: at 24 Weeks
Overall response rate is defined as the proportion of patients who demonstrate complete or partial responses in injected lesions per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria appropriate for cutaneous neoplasms (ORR=complete response + partial response).
次要结局
- Progression-free Survival(up to 2 years)
- Analyses of Immune Infiltration Within Resected Tumor Specimens(Baseline to 2 years)
- Complete Response Rate(Baseline to 2 years)
- Duration of Response(at 4 weeks)
- T-VEC Treated Tumors Requiring Surgical Resection(Baseline to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu NegativeInvasive Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Recurrent Breast CarcinomaNCT03554044University of California, San Francisco20
进行中（未招募）
2 期
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaEpithelioid SarcomaCutaneous AngiosarcomaSarcomaNCT03069378Memorial Sloan Kettering Cancer Center41
已完成
2 期
Study of TVEC in Patients With Cutaneous Squamous Cell CancerSkin Cancer, Squamous CellLesion SkinCutaneous TumorKeratoacanthomaSkin CancerSquamous Cell CarcinomaNCT03714828University of Arizona11
进行中（未招募）
2 期
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgerySarcoma G2Sarcoma G3LeiomyosarcomaSoft Tissue SarcomaSoft Tissue Sarcoma of the Trunk and ExtremitiesStage I Soft Tissue Sarcoma AJCC v7Stage II Soft Tissue Sarcoma AJCC v7Undifferentiated Pleomorphic SarcomaLiposarcomaNCT02923778National Cancer Institute (NCI)40
终止
1 期
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal CancerLocally Advanced Rectal AdenocarcinomaMetastatic Rectal AdenocarcinomaRectal AdenocarcinomaStage III Rectal Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7Stage IIIB Rectal Cancer AJCC v7Stage IIIC Rectal Cancer AJCC v7Stage IV Rectal Cancer AJCC v7Stage IVA Rectal Cancer AJCC v7Stage IVB Rectal Cancer AJCC v7NCT03300544National Cancer Institute (NCI)3